Mavacamten Reduces Obstructive HCM in Youth
A global clinical trial has revealed that mavacamten, a heart medication previously approved for adults, safely and effectively improves blood flow in the left ventricles of youth with hypertrophic cardiomyopathy. This groundbreaking finding, the first phase 3 trial of its kind for pediatric HCM, offers a precision medicine approach that could help many young patients avoid invasive open-heart surgery.